Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene by Tzur, Shay et al.




Missense mutations in the APOL1 gene are highly associated 
with end stage kidney disease risk previously attributed 
to the MYH9 gene
Shay Tzur · Saharon Rosset · Revital Shemer · Guennady Yudkovsky · 
Sara Selig · Ayele Tarekegn · Endashaw Bekele · Neil Bradman · 
Walter G. Wasser · Doron M. Behar · Karl Skorecki 
Received: 7 June 2010 / Accepted: 6 July 2010 / Published online: 16 July 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract MYH9 has been proposed as a major genetic
risk locus for a spectrum of nondiabetic end stage kidney
disease (ESKD). We use recently released sequences from
the 1000 Genomes Project to identify two western African-
speciWc missense mutations (S342G and I384M) in the
neighboring APOL1 gene, and demonstrate that these are
more strongly associated with ESKD than previously
reported MYH9 variants. The APOL1 gene product, apoli-
poprotein L-1, has been studied for its roles in trypanoso-
mal lysis, autophagic cell death, lipid metabolism, as well
as vascular and other biological activities. We also show
that the distribution of these newly identiWed APOL1 risk
variants in African populations is consistent with the
pattern of African ancestry ESKD risk previously attributed
to MYH9.
Mapping by admixture linkage disequilibrium (MALD)
localized an interval on chromosome 22, in a region that
includes the MYH9 gene, which was shown to contain
African ancestry risk variants associated with certain forms
of ESKD (Kao et al. 2008; Kopp et al. 2008).  MYH9
encodes nonmuscle myosin heavy chain IIa, a major cyto-
skeletal nanomotor protein expressed in many cell types,
including podocyte cells of the renal glomerulus. More-
over, 39 diVerent coding region mutations in MYH9 have
been identiWed in patients with a group of rare syndromes,
collectively termed the Giant Platelet Syndromes, with
clear autosomal dominant inheritance, and various clinical
manifestations, sometimes also including glomerular
pathology and chronic kidney disease (Kopp 2010; Sekine
et al. 2010). Accordingly, MYH9 was further explored in
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these studies as the leading candidate gene responsible for
the MALD signal. Dense mapping of MYH9 identiWed indi-
vidual single nucleotide polymorphisms (SNPs) and sets of
such SNPs grouped as haplotypes that were found to be
highly associated with a large and important group of
ESKD risk phenotypes, which as a consequence were
designated as MYH9-associated nephropathies (Bostrom
and Freedman 2010). These included HIV-associated
nephropathy (HIVAN), primary nonmonogenic forms of
focal segmental glomerulosclerosis, and hypertension
aYliated chronic kidney disease not attributed to other
etiologies (Bostrom and Freedman 2010). The MYH9 SNP
and haplotype associations observed with these forms of
ESKD yielded the largest odds ratios (OR) reported to date
for the association of common variants with common dis-
ease risk (Winkler et al. 2010). Two speciWc MYH9 variants
(rs5750250 of S-haplotype and rs11912763 of F-haplotype)
were designated as most strongly predictive on the basis of
Receiver Operating Characteristic analysis (Nelson et al.
2010). These MYH9 association studies were then also
extended to earlier stage and related kidney disease pheno-
types and to population groups with varying degrees of
recent African ancestry admixture (Behar et al. 2010;
Freedman et al. 2009a, b; Nelson et al. 2010), and led to the
expectation of Wnding a functional African ancestry causa-
tive variant within MYH9. However, despite intensive
eVorts including re-sequencing of the MYH9 gene no sug-
gested functional mutation has been identiWed (Nelson
et al. 2010; Winkler et al. 2010). This led us to re-examine
the interval surrounding MYH9 and to the detection of
novel missense mutations with predicted functional eVects
in the neighboring APOL1 gene, which are signiWcantly
more associated with ESKD than all previously reported
SNPs in MYH9.
SNPs and haplotypes for analysis in previous studies
were taken from the HapMap databases available at the
time of study (http://www.hapmap.org). These antedated
the release and availability of more extensive and detailed
DNA diversity information from complete genomic
sequences currently available through the 1000 Genomes
Project (http://www.1000genomes.org), which in particular
provide an enriched sampling of SNPs that are rare in
Europe compared to the reported HapMap SNPs, and there-
fore especially useful for our purposes. Therefore, upon
availability of the March 2010 release of the 1000 Genomes
Project, we analyzed 119 whole genome sequences of
which 60 are of European origin (CEU), and 59 are of
West-African origin (YRI), yielding a total of 7,479 SNPs
in the 1.55 Mbp chromosome 22 interval surrounding
MYH9 and spanning nucleotide positions 34,000,000–
35,550,000 (NCBI36). We then applied Wltering criteria to
identify candidates for further consideration and analysis
based on (1) low allele frequency in CEU but not in YRI
and (2) linkage disequilibrium (LD) patterns with the previ-
ously identiWed leading MYH9 risk variants (see supple-
mentary material). Of the 250 variants that met these
criteria, four are coding region nonsynonymous mutations
(Table 1), none of which were reported in HapMap. The
Wrst two SNPs (rs73885319 and rs60910145) are missense
mutations in the last exon of the APOL1 gene (S342G and
I384M) which is the neighboring gene, located 14 kbp 3
downstream from MYH9. A third SNP (rs11089781) is a
nonsense mutation (Q58X) in the APOL3 gene located 110
kbp further 3 downstream. The fourth SNP (rs56767103)
is a missense mutation (R71C) in the gene FOXRED2
located 100 kbp upstream to the 5 side of MYH9 (Supple-
mentary Fig. 1). Of note, the two variants located 128 bp
apart in APOL1 are in almost perfect LD (237 out of 238
chromosomes from the 1000 Genomes Project).
These four variants were genotyped in a previously
reported composite sample set of 955 subjects taken from
two diVerent populations, namely African American and
Hispanic American cases and controls (Behar et al. 2010)
(supplementary material). In this composite sample set,
subjects with ESKD etiologies designated as MYH9-associ-
ated nephropathies as deWned above, and notably excluding
diabetic nephropathy, which was not previously found to be
associated with MYH9 (Behar et al. 2010; Kao et al. 2008;
Kopp et al. 2008), were designated as cases (n = 430). Sub-
jects without known kidney disease and a creatinine con-
centration below 1.7 at age 55 or greater were designated as
controls (n = 525). Associations of the candidate mutations
with these ESKD phenotypes, previously attributed to
MYH9, was determined using logistic regression, with cor-
rection for global and local ancestry, and considering three
modes of inheritance as previously reported (Behar et al.
2010). It should be noted that the four variants were geno-
typed for the two population sources using two diVerent
techniques each conducted in a separate laboratory, and
with sequence validation of the genotyping method (Sup-
plementary Fig. 6). We chose to use two diVerent popula-
tion sources, African American and Hispanic American,
with markedly diVering degrees of global African ancestry
admixture (Bedoya et al. 2006; Behar et al. 2010), rather
than two diVerent collections from the same population, in
order to test whether associations were robust to diVering
global background genomic composition.
Table 1 shows the association results for the combined
dataset of the African American and Hispanic American
cohorts. For comparison, we include the results from the
two previously reported leading MYH9 risk variants as
noted above (S-1 rs5750250, F-1 rs11912763) (Nelson
et al. 2010). We found that the APOL1 missense variants
(rs73885319 and rs60910145) are more strongly associated
with ESKD risk than the leading MYH9 risk variants, both
in terms of OR and p values (Table 1). In contrast, theHum Genet (2010) 128:345–350 347
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lower allele frequency and OR, with a higher p value for
the APOL3 nonsense variant, and the weak association for
the FOXRED2 missense mutation, render these variants to
be very unlikely candidates to explain the risk attributed to
this genomic region. For the highly associated APOL1 mis-
sense mutations, the risk allele frequency in the African
American control cohort is 21% in contrast to 37% in the
cases (corresponding values for Hispanic Americans are 6
and 23%, respectively). The most striking diVerence is in
the frequency of the homozygote risk state, with only 3% in
controls compared to 18% in cases for African Americans
(corresponding values for Hispanic Americans are 0.5 and
11%, respectively) (see also Supplementary Fig. 5). We
also show that the results for combined and meta-analysis
of the two separate cohort-based results are congruent
(Supplementary Table 1). As also evident from Table 1 and
Supplementary Table 1, the modes of inheritance for which
the associations of the disease risk phenotype with the
APOL1 missense mutations are signiWcant is consistent
with an additive eVect, wherein carrying the missense
mutations on a single parental allele is suYcient to confer
signiWcantly increased risk, but with a still greater jump in
risk conferred by carrying the missense mutations on both
parental alleles. As noted above, the two missense muta-
tions are in nearly perfect LD, and therefore, on a popula-
tion genetics basis alone they can be considered as
designating a “missense risk haplotype”. Examination of
the predicted eVect on protein structure and functional stud-
ies with artiWcial constructs which separate the two mis-
sense mutations will determine whether disease risk relates
to either or both together as a functional missense haplo-
type. Therefore, for further analysis in the current study, we
go on to use APOL1 SNP rs73885319 as tagging the “mis-
sense risk haplotype”. Analysis of deviance of the com-
bined logistic regression indicates that LD with APOL1
SNP rs73885319 accounted for most of the statistical asso-
ciation previously attributed to the leading MYH9 variants
with ESKD (supplementary material). In this regard, we
also examined two noncoding variants in the APOL1 region
which are in high LD with the APOL1 missense mutations,
and as expected, both showed signiWcant disease risk asso-
ciation (Supplementary Fig. 2; Supplementary Table 1).
Table 1 Association with nondiabetic ESKD of nonsynonymous SNPs in APOL1, APOL3, and FOXRED2 in the MALD peak and comparison
with leading MYH9 SNPs
a Location on Chromosome 22 in NCBI36 assembly
b African ESKD “risk” state in bold
c Frequencies according to available 1000 Genomes data
d Association results were derived using logistic regression, correcting for global and local African ancestry, and combining the Hispanic and Afri-
can American cohorts. See supplementary text for details
e See Supplementary Fig. 5 for allele frequency pie-charts in cases versus controls
rs number Gene Type Chr22 
locationa




Moded OR p value
rs73885319e APOL1 exon 5 34,991,852 A/G 46 0 Recessive 6.7 2.71E¡06
S342G missense Additive 2.22 2.38E¡08
Dominant 2.23 8.11E¡06
rs60910145 APOL1 exon 5 34,991,980 T/G 45 0 Recessive 6.74 9.89E¡06
I384M missense Additive 2.28 3.00E¡08
Dominant 2.32 4.75E¡06
rs11089781 APOL3 exon 1 34,886,714 G/A 31 0 Recessive 6.62 2.82E¡03
Q58X nonsense Additive 2.18 3.79E¡06
Dominant 2.22 3.23E¡05
rs56767103 FOXRED2 exon 1 35,232,205 G/A 18 0 Recessive 1.33 6.83E¡01
R71C missense Additive 1.52 5.19E¡02
Dominant 1.66 3.64E¡02
rs11912763 MYH9 intron 33 35,014,668 G/A 48 0 Recessive 2.38 2.86E¡02
F-1 designation Additive 1.96 4.05E¡05
Dominant 2.28 4.20E¡05
rs5750250 MYH9 intron13 35,038,429 A/G 66 6 Recessive 2.48 4.29E¡05
S-1 designation Additive 1.78 6.68E¡05
Dominant 1.55 4.97E¡02348 Hum Genet (2010) 128:345–350
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HIVAN has been considered as the most prominent of
the nondiabetic forms of kidney disease within what has
been termed the MYH9-associated nephropathies (Kopp
et al. 2008; Winkler et al. 2010). We have reported absence
of HIVAN in HIV infected Ethiopians, and attributed this
to host genomic factors (Behar et al. 2006). Therefore, we
examined the allele frequencies of the APOL1 missense
mutations in a sample set of 676 individuals from 12
African populations, including 304 individuals from four
Ethiopian populations (Supplementary Table 2). We cou-
pled this with the corresponding distributions for the
African ancestry leading MYH9 S-1 and F-1 risk alleles.
A pattern of reduced frequency of the APOL1 missense
mutations and also of the MYH9 risk variants was noted in
northeastern African in contrast to most central, western,
and southern African populations examined (Supplemen-
tary Fig. 3). Especially striking was the complete absence
of the APOL1 missense mutations in Ethiopia. This combi-
nation of the reported lack of HIVAN and observed
absence of the APOL1 missense mutations is consistent
with  APOL1 being the functionally relevant gene for
HIVAN risk and likely the other forms of kidney disease
previously associated with MYH9.
The  APOL1 gene encodes apolipoprotein L-1, whose
known activities include powerful trypanosome lysis
(Vanhamme et al. 2003), autophagic cell death (Wan et al.
2008), lipid metabolism, cellular senescence, as well as
vascular and other biological activities (Monajemi et al.
2002; Vanhollebeke and Pays 2006). Of note, in humans,
APOL1 is one of six closely spaced and related APOL
genes, respectively, encoding six gene products apolipopro-
teins L-1 through L-6 (Duchateau et al. 1997, 2001). While
APOL3 is thought to have arisen Wrst in genomic evolution
of the region, with the others having arisen as a result of
duplication events (Monajemi et al. 2002), only apolipopro-
tein L-1 has a signal peptide which enables it to be both a
circulating and intracellular protein (Vanhollebeke and
Pays 2006). This latter capacity is of crucial importance to
the protective and lytic activity of human serum to many
species of trypanosoma. Trypanosoma brucei rhodesiense
transmitted by tsetse Xies causes human African trypanoso-
miasis as a result of the expression of serum resistance
associated protein (SRA), which interacts with the C-termi-
nal domain of apolipoprotein L-1 and inactivates its lytic
function (Lecordier et al. 2009). Apolipoprotein L-1 protein
structure is divided into three distinctive structural and
functional domains: (1) an anionic pore-forming domain
which is thought to be involved in organellar permeation
and cell death, (2) a membrane addressing-domain consist-
ing of a pH-sensitive hairpin bridging two alpha helices
which facilitates association with the circulating HDL par-
ticle at neutral pH and intracellular organellar localization
at acidic pH, and 3) a C-terminus amphipathic alpha helix
with a leucine zipper for protein–protein interaction
(Vanhollebeke and Pays 2006). It should be noted that the
APOL1 S342G variant, powerfully associated with kidney
disease risk in the current study, is predicted to modify the
binding site of the C-terminus domain of the APOL1 gene
product (Supplementary Fig. 4).
With respect to kidney disease risk, apolipoprotein L-1
is also prominently involved in autophagic pathways
(Zhaorigetu et al. 2008), and a recent study has provided
compelling evidence for the role of well-preserved
autophagy in the integrity of renal glomerular podocytes
(Hartleben et al. 2010). It is thus possible that variation in
the C-terminus domain of endogenously expressed or endo-
cytosed apolipoprotein L-1 modiWes interaction with an as
yet unidentiWed renal intracellular protein, which regulates
the availability of apolipoprotein L-1 in its pore-forming or
other functions. Given the numerous known functions of
apolipoprotein L-1 noted above, a number of other mecha-
nisms for kidney disease risk are possible, including those
related to lipid metabolism or vascular integrity (Monajemi
et al. 2002). The involvement of other classes of apolipo-
proteins in nephropathy has been well documented
(Takemura et al. 1993). Moreover, apolipoproteins have
also been identiWed as circulating inhibitors of glomerular
proteinuria (Candiano et al. 2001). Remarkably, in this lat-
ter study, the amino acid sequence of the apolipoprotein L
fraction isolated and studied corresponds exactly to what
we now know to be apolipoprotein L-1.
Functional assays of the eVect of the APOL1 missense vari-
ants described herein in appropriate experimental model sys-
tems will be needed to link the strong and biologically
plausible association to a functional pathogenic pathway in
kidney disease and to the possible selective factors which con-
tributed to the observed African allele frequency distribution.
It is noteworthy that this entire region of the genome
shows a high degree of LD and evidence of strong evolu-
tionary selection, which may well explain why MYH9
yielded such a strong association signal in prior studies due
to a hitchhiking eVect of MYH9 with variants in the APOL
gene family that have conferred adaptive advantage (Gross-
man et al. 2010; Smith and Malik 2009; Stephan et al.
2006). It should also be noted that the expression of apoli-
poproteins L in vascular and immune cells is greatly
increased by viral infections, interferons, and inXammatory
mediators (Vanhollebeke and Pays 2006), any or all of
which might constitute the basis for a second “trigger”
needed to induce the actual clinical manifestation of
nephropathy in a genotypically “at risk” individual. More-
over, given the close evolutionary relationship of the six
members of the human apolipoprotein L family and their
manifold and overlapping functions, it is conceivable that
additional rare or common variants might also interact and
be involved in kidney disease risk (Supplementary Table 3).Hum Genet (2010) 128:345–350 349
123
The current Wndings strongly suggest that the intensive
eVorts (http://www3.niddk.nih.gov/fund/other/MYH9
KidneyDisease/) currently underway to identify the ESKD
disease phenotype risk causative variant in the chromosome
22 MALD peak should certainly be extended beyond the
MYH9 locus. In particular, a strong emphasis should also be
placed on APOL1 mutations with strong association and
functional plausibility.
Methods and supplementary information and any
associated references are available on the Human Genetics
website:  http://www.springer.com/biomed/human+genetics/
journal/439.
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